ERBB2 and neoplasm: Several molecular mechanisms are involved in the resistance to anoikis of tumor cells, including survival signaling driven by PI3K and NF-κB pathways, the expression of anti-apoptotic proteins such as Bcl-2, and the hyperactivation of tyrosine kinase receptors such as EGFR and ErbB2 [26].